Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003463 · ClinicalTrials.gov registry record · Phase 1
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003463: Completed Phase 1 study, sponsored by Duke University.
NCT00003463 is a Phase 1 study that has completed, run by Duke University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003463, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in treating patients with recurrent supratentorial high grade gliomas.
Interventions
- DRUG carmustine
- DRUG irinotecan hydrochloride
- PROCEDURE surgical procedure
- DRUG polifeprosan 20 with carmustine implant
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-07 |
| Est. Completion | 2002-07 |
| Phase | Phase 1 |
What the finished NCT00003463 record still lists
NCT00003463 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which carmustine is the first listed.
NCT00003463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003463 about?
NCT00003463 is a clinical study titled "Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in treating patients with recurrent ...
What is the current status of trial NCT00003463?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-07. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00003463?
The interventions under investigation include: carmustine (DRUG), irinotecan hydrochloride (DRUG), surgical procedure (PROCEDURE), polifeprosan 20 with carmustine implant (DRUG).
Who is sponsoring clinical trial NCT00003463?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia